ATE507831T1 - Melatonin enthaltende pharmazeutische formulierung - Google Patents

Melatonin enthaltende pharmazeutische formulierung

Info

Publication number
ATE507831T1
ATE507831T1 AT03746393T AT03746393T ATE507831T1 AT E507831 T1 ATE507831 T1 AT E507831T1 AT 03746393 T AT03746393 T AT 03746393T AT 03746393 T AT03746393 T AT 03746393T AT E507831 T1 ATE507831 T1 AT E507831T1
Authority
AT
Austria
Prior art keywords
pharmaceutical formulation
formulation containing
containing melatonin
melatonin
pharmaceutical
Prior art date
Application number
AT03746393T
Other languages
English (en)
Inventor
Nava Zisapel
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29227410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE507831(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Application granted granted Critical
Publication of ATE507831T1 publication Critical patent/ATE507831T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03746393T 2002-04-28 2003-03-20 Melatonin enthaltende pharmazeutische formulierung ATE507831T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL149377A IL149377A (en) 2002-04-28 2002-04-28 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
PCT/IL2003/000240 WO2003086352A1 (en) 2002-04-08 2003-03-20 Pharmaceutical formulation comprising melatonin

Publications (1)

Publication Number Publication Date
ATE507831T1 true ATE507831T1 (de) 2011-05-15

Family

ID=29227410

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03746393T ATE507831T1 (de) 2002-04-28 2003-03-20 Melatonin enthaltende pharmazeutische formulierung

Country Status (29)

Country Link
US (1) US20050175692A1 (de)
EP (1) EP1494650B1 (de)
JP (1) JP2005527583A (de)
KR (1) KR101000624B1 (de)
CN (1) CN100386070C (de)
AR (1) AR039232A1 (de)
AT (1) ATE507831T1 (de)
AU (1) AU2003227304B2 (de)
BR (1) BR0308762A (de)
CA (1) CA2477516C (de)
DE (1) DE60336999D1 (de)
DK (1) DK1494650T3 (de)
EA (1) EA007954B1 (de)
ES (1) ES2366116T3 (de)
GT (1) GT200300064A (de)
HN (1) HN2003000115A (de)
IL (1) IL149377A (de)
IS (1) IS2858B (de)
MX (1) MXPA04009893A (de)
NO (1) NO332525B1 (de)
NZ (1) NZ536298A (de)
PE (1) PE20040161A1 (de)
PL (1) PL209922B1 (de)
PT (1) PT1494650E (de)
TW (1) TW200305404A (de)
UA (1) UA86924C2 (de)
UY (1) UY27753A1 (de)
WO (1) WO2003086352A1 (de)
ZA (1) ZA200407563B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1696959A2 (de) * 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin-kombinationstherapie zur verbesserung der schlafqualität
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder
US20060198872A1 (en) * 2005-03-07 2006-09-07 Chioma Ikonte Plant based dietary supplement for improving the duration and quality of sleep
KR20070070307A (ko) * 2005-08-24 2007-07-04 에스에스 세야쿠 가부시키 가이샤 수면 개선 의약 조성물
CN1299680C (zh) * 2005-08-29 2007-02-14 陈彦方 一种治疗失眠的黑白制剂
AR056076A1 (es) * 2005-09-20 2007-09-19 Takeda Pharmaceutical Agente profilactico o terapeutico para el desorden de sueno
CN102018681A (zh) * 2010-12-10 2011-04-20 荣港生技医药科技（北京）有限公司 一种美乐托宁缓释剂、其制备方法及其应用
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US9532952B2 (en) * 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
EP2570126B1 (de) 2011-09-16 2014-03-26 Darius Rassoulian Verwendung von Melatonin zur Behandlung akuter Alkoholvergiftung
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
DK3337462T3 (da) 2016-10-31 2020-10-12 Neurim Pharma 1991 Melatonin-minitabletter og fremgangsmåde til fremstilling heraf
CN109364031A (zh) * 2018-10-07 2019-02-22 威海贯标信息科技有限公司 一种盐酸曲唑酮片剂组合物
EP4090315A1 (de) * 2020-01-17 2022-11-23 Société des Produits Nestlé S.A. Dosierungsform mit melatoninpellets mit verzögerter freisetzung

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
US5707652A (en) * 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
FR2718020B1 (fr) * 1994-04-01 1996-05-31 Biotec Centre Sa Composition galénique mucoadhésive hétérofonctionnelle.
MD1716C2 (ro) * 1995-02-01 2002-02-28 Neurim Pharmaceuticals (1991) Ltd. Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine
WO1997032871A1 (en) * 1996-03-08 1997-09-12 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
AU2583397A (en) * 1996-04-10 1997-10-29 Chronorx, Llc Unit dosage forms, containing magnesium, vitamin c, vitamin e, folate and selenium, for treatment of vasoconstriction and related conditions
EP0912174B1 (de) * 1996-07-17 2004-04-28 MERCK & CO., INC. Änderung des zirkadischen rhythmus mit nicht-peptidischen neurokinin-1 rezeptor antagonisten
US6348485B1 (en) * 1998-06-09 2002-02-19 Takeda Chemical Industries, Ltd. Method for treating or preventing sleep disorders
CN1131030C (zh) * 1999-03-18 2003-12-17 胡秀云 一种由褪黑素和安定制成的调节睡眠的组合物
CN1377261A (zh) * 1999-03-22 2002-10-30 免疫力药品有限公司 治疗免疫疾病
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs

Also Published As

Publication number Publication date
NO20043576L (no) 2004-12-22
EP1494650B1 (de) 2011-05-04
DK1494650T3 (da) 2011-08-08
TW200305404A (en) 2003-11-01
EP1494650A1 (de) 2005-01-12
EA200401331A1 (ru) 2005-04-28
ES2366116T3 (es) 2011-10-17
CA2477516A1 (en) 2003-10-23
IS2858B (is) 2013-12-15
UA86924C2 (ru) 2009-06-10
AU2003227304A2 (en) 2005-04-14
IL149377A0 (en) 2009-02-11
EA007954B1 (ru) 2007-02-27
WO2003086352A1 (en) 2003-10-23
JP2005527583A (ja) 2005-09-15
HK1075616A1 (zh) 2005-12-23
IL149377A (en) 2012-10-31
NZ536298A (en) 2008-09-26
CA2477516C (en) 2012-12-11
PL209922B1 (pl) 2011-11-30
EP1494650A4 (de) 2006-07-12
HN2003000115A (es) 2004-04-20
KR20040101406A (ko) 2004-12-02
PT1494650E (pt) 2011-08-18
AR039232A1 (es) 2005-02-09
GT200300064A (es) 2003-11-26
DE60336999D1 (de) 2011-06-16
US20050175692A1 (en) 2005-08-11
IS7492A (is) 2004-10-07
CN1646098A (zh) 2005-07-27
KR101000624B1 (ko) 2010-12-10
PL372867A1 (en) 2005-08-08
NO332525B1 (no) 2012-10-08
AU2003227304B2 (en) 2007-12-06
CN100386070C (zh) 2008-05-07
AU2003227304A1 (en) 2003-10-27
UY27753A1 (es) 2003-05-30
PE20040161A1 (es) 2004-03-22
ZA200407563B (en) 2005-11-30
MXPA04009893A (es) 2005-06-17
BR0308762A (pt) 2005-01-11

Similar Documents

Publication Publication Date Title
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
ATE372765T1 (de) Feste pharmazeutische formulierungen mit telmisartan
ATE460169T1 (de) Pharmazeutische formulierung mit lanthanum- verbindungen
PT1501534E (pt) Formulacoes farmaceuticas
DE602004016967D1 (de) Flüssige pharmazeutische palonosetronformulierungen
ATE317260T1 (de) Pharmazeutische formulierungen mit platinderivaten
EP1477403A4 (de) Arzneimittelversorgung
NO20033384D0 (no) Farmasöytisk formulering
ATE334656T1 (de) Flüssige pharmazeutische zusammensetzung
DE60332393D1 (de) Flüssige pharmazeutische zusammensetzung mit pyridonderivaten
DE60308372D1 (de) Dosierungsverabreichungsvorrichtung
DE60312049D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
DE60315939D1 (de) Pharmazeutische zusammensetzung enthaltend ein androgen
ATE320807T1 (de) Pharmazeutische zusammensetzungen enthaltend tegaserod
NO20035627D0 (no) Farmasöytisk formulering
ITTO20010005A1 (it) Formulazione farmaceutica.
ATE477814T1 (de) Stabile faktor-viii enthaltende pharmazeutische zusammensetzung
DE60336999D1 (de) Melatonin enthaltende pharmazeutische formulierung
ATE327759T1 (de) Pharmazeutische zusammensetzung mit verlungerter freisetzung
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE60328119D1 (de) Pharmazeutische zubereitungen enthaltend modafinil
DE60310526D1 (de) Ivabradin enthaltende pharmazeutische zusammensetzung mit oraler dispersion
ATE332690T1 (de) Perindopril enthaltende pharmazeutische zusammensetzung mit oraler dispersion
DE60328787D1 (de) Pharmazeutische salze von reboxetin
DE10291905D2 (de) Pharmazeutische Zusammensetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1494650

Country of ref document: EP